

Haichuan Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8825849/publications.pdf>

Version: 2024-02-01

48
papers

4,214
citations

159585

30
h-index

254184

43
g-index

48
all docs

48
docs citations

48
times ranked

6751
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. <i>Nature Medicine</i> , 2016, 22, 262-269.	30.7	768
2	<i>RET</i> Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4352-4359.	1.6	483
3	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies. <i>Clinical Cancer Research</i> , 2015, 21, 3924-3933.	7.0	459
4	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 567.	2.0	206
5	ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. <i>Lung Cancer</i> , 2014, 84, 121-126.	2.0	194
6	Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis. <i>Clinical Cancer Research</i> , 2012, 18, 1947-1953.	7.0	161
7	Genomic and immune profiling of pre-invasive lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 5472.	12.8	127
8	PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup. <i>PLoS ONE</i> , 2014, 9, e88291.	2.5	126
9	FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4107-4114.	7.0	125
10	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. <i>Cancer Cell</i> , 2021, 39, 1531-1547.e10.	16.8	106
11	Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. <i>Lung Cancer</i> , 2013, 79, 8-13.	2.0	102
12	The Use of Quantitative Real-Time Reverse Transcriptase PCR for 5' and 3' Portions of <i>ALK</i> Transcripts to Detect <i>ALK</i> Rearrangements in Lung Cancers. <i>Clinical Cancer Research</i> , 2012, 18, 4725-4732.	7.0	86
13	Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains. <i>Journal of Thoracic Oncology</i> , 2012, 7, 85-89.	1.1	82
14	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. <i>Clinical Cancer Research</i> , 2018, 24, 197-208.	7.0	74
15	Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. <i>Oncotarget</i> , 2015, 6, 34300-34308.	1.8	70
16	A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1772-1778.	1.1	69
17	MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer. <i>Oncotarget</i> , 0, 7, 41691-41702.	1.8	68
18	Integrative Proteomics and Tissue Microarray Profiling Indicate the Association between Overexpressed Serum Proteins and Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e51748.	2.5	58

#	ARTICLE	IF	CITATIONS
19	Gefitinib as neoadjuvant therapy for resectable stage II-IIIa non-small cell lung cancer: A phase II study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 434-442.e2.	0.8	58
20	Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1444-1450.	1.1	56
21	Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas. <i>Journal of Thoracic Oncology</i> , 2014, 9, 760-768.	1.1	53
22	Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: A single-institution experience. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 778-786.	0.8	52
23	ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR. <i>PLoS ONE</i> , 2013, 8, e69016.	2.5	52
24	Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. <i>Scientific Reports</i> , 2015, 5, 14237.	3.3	51
25	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2579-2586.	1.4	51
26	Putatively Functional PLCE1 Variants and Susceptibility to Esophageal Squamous Cell Carcinoma (ESCC): A Case-Control Study in Eastern Chinese Populations. <i>Annals of Surgical Oncology</i> , 2012, 19, 2403-2410.	1.5	50
27	Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma. <i>Annals of Surgery</i> , 2018, 267, 826-832.	4.2	49
28	The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. <i>Scientific Reports</i> , 2014, 4, 7163.	3.3	42
29	Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1423.	2.0	41
30	A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer. <i>Journal of Proteomics</i> , 2011, 74, 528-538.	2.4	38
31	Comprehensive Analysis of Oncogenic Mutations in Lung Squamous Cell Carcinoma With Minor Glandular Component. <i>Chest</i> , 2014, 145, 473-479.	0.8	36
32	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. <i>OncoTargets and Therapy</i> , 2014, 7, 513.	2.0	32
33	Clinical Significance of Complex Glandular Patterns in Lung Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 65-73.	0.7	31
34	Polymorphisms in the ERCC5 Gene and Risk of Esophageal Squamous Cell Carcinoma (ESCC) in Eastern Chinese Populations. <i>PLoS ONE</i> , 2012, 7, e41500.	2.5	30
35	Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old. <i>Journal of Thoracic Disease</i> , 2014, 6, 1396-402.	1.4	27
36	Clinical and genetic features of lung squamous cell cancer in never-smokers. <i>Oncotarget</i> , 2016, 7, 35979-35988.	1.8	22

#	ARTICLE	IF	CITATIONS
37	Synchronous Non-small Cell Lung Cancers: Diagnostic Yield can be Improved by Histologic and Genetic Methods. <i>Annals of Surgical Oncology</i> , 2014, 21, 4369-4374.	1.5	21
38	Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinoma. <i>OncoTargets and Therapy</i> , 2014, 7, 2127.	2.0	18
39	Is anterior mediastinum route a shorter choice for esophageal reconstruction? A comparative anatomic study. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 40, 1466-9.	1.4	17
40	Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials. <i>OncoTargets and Therapy</i> , 2013, 6, 1771.	2.0	7
41	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1284-1291.	1.5	7
42	The Histologic Classifications of Lung Adenocarcinomas Are Discriminable by Unique Lineage Backgrounds. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2161-2172.	1.1	7
43	RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of NSCLC. <i>Chest</i> , 2012, 142, 593A.	0.8	1
44	Sequential Treatment of Tyrosine Kinase Inhibitors and Chemotherapy for EGFR-Mutated Non-small Cell Lung Cancer: A Meta-analysis of Phase III Trials. <i>Chest</i> , 2014, 145, 348A.	0.8	1
45	Reply to Thakkar et al.. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, 906-906.	1.4	0
46	Frequency of Well-Identified Oncogenic Driver Mutations in Lung Adenocarcinoma of Smokers Varies With Histological Subtypes in Line With IASLC/ATS/ERS Classification. <i>Chest</i> , 2012, 142, 923A.	0.8	0
47	Clinicopathological Characteristics of Non-small Cell Lung Cancer Patients With Primary Concomitant EGFR T790M Mutation. <i>Chest</i> , 2014, 145, 350A.	0.8	0
48	Unlocking Better Survival for Esophageal Cancer Patients: Is Thoracic Duct Resection the Key?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4086-4087.	1.5	0